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Lumbar radiculopathy is a very frequent spine pathology. It
afﬂicts people of all ages and it is mainly responsible for lower
back pain, an often disabling symptom which in the end has a
high impact in daily activities and in terms of economic costs.
Causes are degenerative, regarding alterations of vertebral
structures (both bone-cartilage and nerve-root), but may also
be neoplastic, inﬂammatory, dismetabolic and other causes.
Degenerative causes can be of surgical pertinence or not:
surgical ones are mainly due to herniated discs and lumbar
canal stenosis as well as spondylolisthesis. Generally, we refer
to spondyloarthrosis, spondylo-discarthrosis, and disc protru-
sion, as terms to deﬁne all nonsurgical degenerative spine
disorders in which lower back pain symptoms are prevalent,* Corresponding author.
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pain relief drugs and physiotherapic support therapies can be
helpful. One type of pharmacological therapy using micron-
ized palmitoylethanolamide has long since been considered,
exploiting the anti-inﬂammatory action of this compound on
non-neuronal cells like mastcells and microglial neurons [1]. In
this work we present a casuistry composed of nonsurgical
lumbar radiculopathies treated with PEA and the relative
obtained results.
2. Materials and methods
We analyzed retrospectively a number of 100 cases of patients
with a long history of lower back pain with or without sciatica,
composed of 73 males and 27 females, 45 and 75 years old,hotmail.it (P. Chirchiglia), fsignorelli@unicz.it (F. Signorelli).
p. z o.o. All rights reserved.
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lumbar radicular compression such as reduction or abolition of
tendon reﬂexes, decrease in muscle strength, in some cases so
severe to force the patient to stay in bed. Radiological
diagnostic (Radiography) procedures showed more or less
marked signs of spondylosis in all patients and CT scans and
spine MRI conﬁrmed vertebral bone alterations, as well as
modiﬁcations in all structures like intervertebral disc, consti-
tuting by black disc, disc protrusion, and dehydration disc.
Laboratory results were in the standard. Furthermore, all
subjects underwent diagnostic neurophysiological assess-
ment (Needle EMG, nerve conduction velocities), which
showed electrophysiological signs of radicular ache in less
than half of cases. Then, the patients underwent pain
evaluation, using Visual Analogic Scale (VAS) that showed a
score between 8 and 10 cm in 72 subjects, 5–6 cm in 14, 2–4 cm
in the fourteen remaining. On the basis of these results, the
radicular compression was divided into mild, moderate and
severe. At this point, a pharmacological protocol was
prescribed, consisting in administration of um-PEA, formulat-
ed as follows: ultramicronized form 1200 mg/die, sachet
confection sublingual use for 10 days, then the same dose in
tablets for the remaining 20 days (Normast® 600 mg micro-
granules and tablets; Epitech Group S.p.A.-Saccolongo, Italy).
The second cycle was for the duration of another month and
consisted in administration of ultramicronized form 600 mg/
die, tablet use. In combination with PEA, in both cycles,
paracetamol 500 mg plus codeine 30 mg/die for 4 days was
used, then only as needed, for 1 month; paracetamol combined
with codeine was used for the second month, at the same dose
only as needed.
3. Results
Results have been as follows: after 1 month of therapy, the
patients with baseline score mild (VAS between 2 and 4; 14
patients), moderate (VAS between 5 and 6; 14 patients) and
severe (VAS between 8 and 10; 72 patients) showed aFig. 1 – Decrease over time of pain intensity observed in 14 pati
between 2 and 4; the mean values move from 3.5 W 0.2 to 1.7 W signiﬁcant (P < 0.0001) decrease of average pain intensity
respectively of 1.9  0.10, 2.7  0.13 and 2.3  0.19. After the
second cycle of therapy, all patients reported a further
improvement in pain, as pointed out by VAS, particularly
those with a mild and moderate score were pain free (Figs. 1
and 2), while the 70.80% of patients considered as severe score
showed an improvement of more than 50% (Fig. 3). Nobody
during the two cycles of therapy reported any adverse effects.
Therefore, the results offered by clinical and pharmacological
data show the effective efﬁcacy of PEA in improving pain
symptomatology in degenerative lumbar radicular compres-
sion, as noted in our report of cases with a total success
percentage of about 80%, with a greater effect on those with
mild and moderate grade of pain.
4. Discussion
Palmitoylethanolamide (PEA) is an endogenous chemical
substance of lipid nature, identiﬁed in the 1990s by the
research group of Nobel Laureate Rita Levi Montalcini as
regulator of mastcell reactivity [2]. It acts on not only neuronal
cells but mastcells and microglial cells as well, modulating
microglial activation and mastcell hyper-reactivity, therefore
having a role in neuroinﬂammation events (ALIA mechanism:
Autacoid Local Injury Antagonism) [2,3]. The pathophysiology
of neuroinﬂammation starts from the interaction between
nociceptive terminations and mastcells. A low control on
mastcell provokes abnormal release of growth factors (with
neo-innervation, angiogenesis), biogenic amines (with devel-
opment of edema), cytokines, causing reduct algogenic
threshold (peripheral sensitization) and neurogenic inﬂam-
mation [4,5]. PEA intervenes in this mechanism, when
esogenous provision is necessary, blocking spinal neuroin-
ﬂammation processes and neuronal plasticity which cause
marked and ampliﬁed modiﬁcations of synaptic transmission
[6]. It is the failure to control this that creates and keeps
neuropathic pain, for which the intervention of PEA is helpful
and necessary. Furthermore, PEA normalizes mastcell de-ents suffering from mild painful symptoms (baseline score
0.1 and to 0). *P < 0.0001.
Fig. 3 – Decrease over time of pain intensity observed in 72 patients, suffering from severe painful symptoms with baseline
score between 8 and 10; the mean values move from 8.7 W 0.10 to 6.4 W 0.15 and to 4.6 W 0.29. *P < 0.0001.
Fig. 2 – Decrease over time of pain intensity observed in 14 patients suffering from moderate painful symptoms with baseline
score between 5 and 6; the mean values move from 5.3 W 0.1 to 2.6 W 0.1 and to 0. *P < 0.0001.
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tissue homeostasys and therefore in a progressive decrease in
endogenous production of PEA leads to an inability to regulate
mastcells and microglial cells, creating pain symptoms [7,8].
Therefore um-PEA (Ultramicronized Palmithoylethanolamide)
is used in those diseases in which the mechanisms of
neuroinﬂammation are present such as neuropathies, by
nerve entrapment [9] or dismetabolic [10], toxic [11] and others
[12–15] and some primary headaches [16]. In this study, we
used um-PEA in degenerative lumbar radiculopathies, a
very frequent disorder, related to alterations involving the
various structures of the lumbar spine, as vertebral body,
intervertebral disc and ligament, which, at the end, cause rootcompression and consequently onset of pain. Edema is an
associated condition, worsening the pain and is a target of um-
PEA pharmacological action, through previously aforemen-
tioned mechanisms. Furthermore, these diseases become
chronic and without surgical intervention the patient has to
live with the pain and take pain relieving drugs such as FANS
and steroids, besides physiotherapic treatments. Our study
shows satisfying results in patients treated with um-PEA, with
an excellent percentage of success, mostly regarding mild and
moderate patients, who appeared as the best responders to
um-PEA therapy. It encourages us to continue the studies on
um-PEA in order to better establish and improve the treatment
and so offer a better quality of life to these patients.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 2 ( 2 0 1 8 ) 4 4 – 4 7 475. Conclusions
This work demonstrates the effectiveness and safety of um-
PEA in lumbar radicular compression, envisaging interesting
future perspectives in pain treatment. Our described cases
showed a good response to therapy, as highlighted by two
months clinical controls, estimated at 80% of patients tested,
mainly in those with mild and moderate chronic pain, which,
at the end of control study, reported no lower back pain or
sciatica. Another aspect worthy of note is the total absence of
side effects. In conclusion, our study, utilizing a discreet
number of patients, showed positive results in lumbar
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